Skip to main
IMVT

Immunovant Inc (IMVT) Stock Forecast & Price Target

Immunovant Inc (IMVT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 14%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Immunovant Inc's focus on developing IMVT-1402 as an FcRn inhibitor demonstrates significant promise in addressing autoimmune diseases, particularly given the sustained reduction in TRAb levels noted during off-treatment periods. The effective responder rate of 81% in a population previously unresponsive to anti-thyroid drugs, along with comparable results to the active treatment period, underscores the potential durability and disease-modifying capabilities of their treatment. These compelling clinical outcomes bolster the positive outlook for Immunovant, reflecting confidence in their innovative approach to managing autoimmune conditions.

Bears say

Immunovant Inc. focuses on developing IMVT-1402 to treat autoimmune diseases driven by high levels of pathogenic IgG antibodies, but challenges persist in the efficacy of their treatment, with high TRabs levels linked to increased relapse rates. The company's reliance on a single operating segment makes it vulnerable to fluctuations in the market and competitive pressures, limiting its growth capacity. Furthermore, potential complications from TRAbs-mediated TSHR activation may result in severe health risks for patients, affecting the company's credibility and long-term viability in the immunology sector.

Immunovant Inc (IMVT) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 14% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunovant Inc (IMVT) Forecast

Analysts have given Immunovant Inc (IMVT) a Buy based on their latest research and market trends.

According to 7 analysts, Immunovant Inc (IMVT) has a Buy consensus rating as of Dec 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunovant Inc (IMVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.